Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03090737 · ClinicalTrials.gov registry record · Phase 2
Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 129
- Enrollment target
- 17
- Study locations
NCT03090737: Completed Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb.
NCT03090737 is a Phase 2 study of Non-Small Cell Lung Cancer that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 129 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (80% lower). The trial reports 17 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03090737, a Phase 2 study of Non-Small Cell Lung Cancer, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 129 participants
- Enrollment target
- 17
- Study locations
Study Summary
A study to evaluate the safety of Nivolumab in participants with advanced or metastatic non-small cell lung cancer
Primary Outcome
The number of participants who experienced at least 1 select AE of Grade 3-5, judged to be related to study drug per investigator with onset on or after first dose of study treatment and within 30 days of last dose of study treatment, divided by number of treated participants. AE grade is defined using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0 criteria. The select AEs consist of pulmonary events, gastrointestinal events, hepatic events, renal event
Conditions Studied
Interventions
- BIOLOGICAL Nivolumab
Study Locations (17)
Ontario
- Local Institution - 0015 - Kingston
- Local Institution - 0014 - Oshawa
- Local Institution - 0001 - Toronto
Other
- Local Institution - 0016 - Tokyo
- Local Institution - 0003 - Craiova
- Local Institution - 0006 - Sector 2
Alabama
- Alabama Oncology - Birmingham
California
- Los Angeles Hematology Oncology Medical Group - Los Angeles
Montana
- St Vincent Frontier Cancer Center - Billings
New York
- Broome Oncology - Johnson City
Pennsylvania
- Guthrie Medical Group Sayre - Sayre
Aichi-ken
- Local Institution - 0017 - Nagoya
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2017-06-02 |
| Est. Completion | 2022-03-14 |
| Phase | Phase 2 |
What the finished NCT03090737 record still lists
NCT03090737 is an interventional study that assigns participants to a tested intervention. The registered 129 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Nivolumab is the first listed.
NCT03090737 lists 17 locations in 13 states (Ontario, Other, Alabama).
Frequently Asked Questions
What is clinical trial NCT03090737 about?
NCT03090737 is a clinical study titled "Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer". A study to evaluate the safety of Nivolumab in participants with advanced or metastatic non-small cell lung cancer
What is the current status of trial NCT03090737?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 129 participants. The study started on 2017-06-02. Estimated completion is 2022-03-14.
What conditions does trial NCT03090737 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT03090737?
The interventions under investigation include: Nivolumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03090737?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03090737 being conducted?
This trial has 17 study locations across Alabama, California, Montana, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03090737's enrollment target sits among peer trials
129 214th of 454 higher than 241 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03619850 · 129 participants · Phase 3
A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
- NCT05704361 · 129 participants · Phase 1
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
- NCT05919849 · 129 participants · Phase 1
Supporting Parents in Affirming Their Children's Experiences of Stigma
- NCT06313749 · 129 participants · NA
Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI